Bio-Thera Solutions, Ltd.

The company is a science-based, global biopharmaceutical company based in Guangzhou, China. Adhering to the concept of “innovation is only for life”, the company is committed to developing a new generation of innovative drugs and biosimilar drugs based on modern biological science research findings to treat tumors, autoimmune diseases, cardiovascular diseases, ophthalmology, and other major diseases that endanger human life or health. The company was officially listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in February 2020. The company is an innovative biopharmaceutical enterprise centered on the development of innovative drugs and biosimilar drugs. Main products: Galeril (adalimumab), purbesi (bevacizumab), schirelli (tocilizumab), and betanin (bevibatide citrate); 2 products have received FDA and EMA approval for marketing: TOFIDANCE (tocilizumab) and Avzivi (bevacizumab). Corporate honors: Guangdong Antibody Drug Coupling Biomedical Engineering Laboratory (Guangdong Engineering Laboratory), Guangdong PhD Workstation, R&D facility construction of Baiaotai Biotechnology (Guangzhou) Co., Ltd., “Most Promising Company” for venture capital in Hong Kong, etc.